SECsense Logo

Travere Therapeutics, Inc. 8-K Report: Key Corporate Developments Revealed

$TVTX
Form 8-K
Filed on: 2025-01-13
Source
Travere Therapeutics, Inc. 8-K Report: Key Corporate Developments Revealed

Based on the provided XML section of the financial report, here are the key pieces of information extracted:

  1. Company Identification:
  • Name: Travere Therapeutics, Inc.
  • CIK Number: 0001438533
  • Entity Type: DE (Delaware Corporation)
  1. Reporting Details:
  • Form Type: 8-K (Current Report)
  • Filing Date: January 13, 2025
  1. Business Address:
  • Address: 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130
  • Phone Number: 888-969-7879
  1. Ticker Symbol and Stock Information:
  • Common Stock Par Value: $0.0001 per share
  • Stock Ticker: TVTX
  • Exchange: NASDAQ
  1. Period of Reporting:
  • Start Date: January 13, 2025
  • End Date: January 13, 2025
  1. Additional Information:
  • The filing is categorized as a Current Report (Form 8-K), which typically indicates that the company is reporting a significant event or corporate change.

Insights:

  • The report is filed on a specific date, indicating it contains timely information about the company, likely related to significant corporate events.
  • Travere Therapeutics, Inc. is positioned in the biotechnology sector, as suggested by its business address and operations likely in pharmaceuticals or therapeutics given its name.
  • The use of the 8-K form signifies that the company may be communicating a noteworthy development, which could be of interest to investors and analysts monitoring the biotech industry.

This information can be vital for investors, stakeholders, and analysts tracking Travere Therapeutics' developments, financial health, and market activity.